Cucurbitacin D

Name: Cucurbitacin D
Brand: MedChemExpress
SKU: HY-N1986
Rating: 4.5 (1 reviews)

Cat. No.: HY-N1986 Purity: 98.41%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Cucurbitacin D is the active ingredient in Trichosanthes kirilowii and can disrupt the interaction between Hsp90 and two co-chaperones, Cdc37 and p23. Cucurbitacin D is an inflammasome activator. Cucurbitacin D induces cell cycle arrest and cell apoptosis, exhibiting anti-tumor and anti-inflammatory effects.

For research use only. We do not sell to patients.

Cucurbitacin D Chemical Structure

CAS No. : 3877-86-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Cucurbitacin D:

Cucurbitacin D (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSP Isoform Specific Products:

View All Isoforms

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

HSP90

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	0.7 μM Compound: 3	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 21459003]
HepG2	IC₅₀	77.33 μM Compound: 3	Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay	[PMID: 21459003]
HepG2	EC₅₀	9 μM Compound: 3	Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay	[PMID: 21459003]
HSC-T6	EC₅₀	0.07 μM Compound: 3	Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay	[PMID: 21459003]
HSC-T6	IC₅₀	26 μM Compound: 3	Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay	[PMID: 21459003]
HT-29	IC₅₀	> 10 μM Compound: 9	Cytotoxicity against human HT-29 cells after 3 days by mitochondrial transmembrane potential assay Cytotoxicity against human HT-29 cells after 3 days by mitochondrial transmembrane potential assay	[PMID: 22239601]
HT-29	IC₅₀	0.12 μM Compound: 9	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 22239601]
JY	IC₅₀	1.36 μM Compound: 4	Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay	[PMID: 7852999]
MCF7	IC₅₀	0.598 μM Compound: 4	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay	[PMID: 25756299]
NCI-H460	IC₅₀	0.12 μg/mL Compound: 5	Antiproliferative activity against human NCI-H460 cells after 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs	[PMID: 17190463]

In Vitro

Cucurbitacin D (0.5 μg/mL, 24 h) combined with doxorubicin can induce apoptosis in MCF7/ADR cells and cause G2/M cell cycle arrest^[1].
Cucurbitacin D (0.125-16 μg/mL, 24-72 h) significantly inhibits the growth of MCF7 and MCF7/ADR cells in a dose- and time-dependent manner^[1].
Cucurbitacin D (0.5-2 μg/mL, 24 h) inhibits STAT3 signaling in MCF7/ADR cells and suppresses the NF-κB signaling pathway^[1].
Cucurbitacin D enhances the production of IL-1β in LPS (HY-D1056) induced THP-1, PECs, BMDMs, and RAW264 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MCF7/ADR induced by doxorubicin
Concentration:	0.5, 2 μg/mL
Incubation Time:	24 h
Result:	Reduced p-STAT3 levels, increased the expression of IκB and NF-κB in the cytoplasm, and reduced the expression of pNF-κB in the nucleus.

Cell Viability Assay^[1]

Cell Line:	MCF7, MCF7/ADR
Concentration:	0.125, 0.5, 2, 4, 8, 16 μg/mL
Incubation Time:	24, 48, 72 h
Result:	Inhibited cell proliferation.

Apoptosis Analysis^[1]

Cell Line:	MCF7/ADR
Concentration:	0.5 μg/mL
Incubation Time:	24 h
Result:	Increased apoptosis by 114%.

Cell Cycle Analysis^[1]

Cell Line:	MCF7/ADR
Concentration:	0.5 μg/mL
Incubation Time:	24 h
Result:	Induced G2/M cell cycle arrest.

In Vivo

Cucurbitacin D (1 mg/kg, intratumoral injection, three times a week for four weeks) inhibits tumor proliferation in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft cervical cancer cell model in nude mice^[3]
Dosage:	1 mg/kg; three times a week; four weeks
Administration:	Intratumoral injection
Result:	Reduced tumor volume and weight, and the expression of pAKT and pSTAT3 proteins was significantly reduced.

Molecular Weight

516.67

Formula

C₃₀H₄₄O₇

CAS No.

3877-86-9

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]([C@@](CC=C(C(C)1C)[C@@]2([H])C[C@H](O)C1=O)([H])[C@@]2(C)C3=O)(C[C@@H](O)[C@]4([H])[C@@](C)(O)C(/C=C/C(C)(O)C)=O)[C@@]4(C3)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 110 mg/mL (212.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9355 mL	9.6774 mL	19.3547 mL
5 mM	0.3871 mL	1.9355 mL	3.8709 mL
10 mM	0.1935 mL	0.9677 mL	1.9355 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.75 mg/mL (5.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.75 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (282 KB) SDS (479 KB)

COA (254 KB) HNMR (227 KB) RP-HPLC (364 KB)

Handling Instructions (2659 KB)

References

[1]. Jin Mo Ku, et al. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Mol Cell Biochem. 2015 Nov;409(1-2):33-43. [Content Brief]

[2]. Yuan Song, et al. Cucurbitacin D is a new inflammasome activator in macrophages. Int Immunopharmacol. 2013 Dec;17(4):1044-50. [Content Brief]

[3]. Mohammed Sikander, et al. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Sci Rep. 2016 Nov 8:6:36594. [Content Brief]

[4]. Hall JA, et al. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery. J Nat Prod. 2015 Apr 24;78(4):873-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9355 mL	9.6774 mL	19.3547 mL	48.3868 mL
	5 mM	0.3871 mL	1.9355 mL	3.8709 mL	9.6774 mL
	10 mM	0.1935 mL	0.9677 mL	1.9355 mL	4.8387 mL
	15 mM	0.1290 mL	0.6452 mL	1.2903 mL	3.2258 mL
	20 mM	0.0968 mL	0.4839 mL	0.9677 mL	2.4193 mL
	25 mM	0.0774 mL	0.3871 mL	0.7742 mL	1.9355 mL
	30 mM	0.0645 mL	0.3226 mL	0.6452 mL	1.6129 mL
	40 mM	0.0484 mL	0.2419 mL	0.4839 mL	1.2097 mL
	50 mM	0.0387 mL	0.1935 mL	0.3871 mL	0.9677 mL
	60 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8064 mL
	80 mM	0.0242 mL	0.1210 mL	0.2419 mL	0.6048 mL
	100 mM	0.0194 mL	0.0968 mL	0.1935 mL	0.4839 mL

Cucurbitacin D Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cucurbitacin D3877-86-9HSPApoptosisHeat shock proteinsCycle arrestapoptosisanti-tumorinflammationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cucurbitacin D

Customer Review

Other Forms of Cucurbitacin D:

Cucurbitacin D Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSP Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Cucurbitacin D Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cucurbitacin D Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report